LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

Accolade To Present at Upcoming Investor Conferences

November 13, 2024 | Last Trade: US$6.89 0.00 0.00

SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days.

  • Stephens Annual Investment Conference | NASH2024 in Nashville on Wednesday, November 20 at 9:00 am CT
  • CG MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21. (1x1 meetings, no webcast)
  • Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5 at 10:00 am ET.

About Accolade, Inc.

Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade’s employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. These offerings are built on a platform that is engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedInTwitter, Instagram and Facebook.

Investor Contact:

Todd Friedman, Investor Relations, This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page